ESC 365 - Anti-inflammatory treatment of COVID-19 patients: which drugs and which patients?

ESC Premium Access

Anti-inflammatory treatment of COVID-19 patients: which drugs and which patients?

Session: Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt?

Topic: Cardiovascular Disease in Special Populations

Speaker: Doctor A. Semb (Oslo, NO)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Doctor Anne Grete Semb

Diakonhjemmet Hospital, Oslo (Norway)

10 presentations

2 followers

4 more presentations in this session

Prevention of thromboembolism in COVID-19.

Speaker: Professor A. Martinez-Rubio (Sabadell, ES)

COVID-19 myocarditis and myocardial injury: active participant or innocent bystander?

Speaker: Professor G. Dan (Bucharest, RO)

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt? – discussion.

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt? - Chat Moderator.

Access the full session

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt?

Speakers: Doctor A. Semb, Professor A. Martinez-Rubio, Professor G. Dan

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources